4-甲基-6-硝基喹啉-2-醇 | 90771-17-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-甲基-6-硝基喹啉-2-醇
• 英文名称: 4-methyl-6-nitro-quinolin-2-ol
• 英文别名: 4-methyl-6-nitroquinolin-2-ol
• CAS: 90771-17-8
• 化学式: C₁₀H₈N₂O₃
• mdl: MFCD01014320
• 分子量: 204.185
• InChiKey: QBBNQTCDZWMPAH-UHFFFAOYSA-N

物化性质

• 熔点：
  340 °C (decomp)
• 沸点：
  434.4±45.0 °C(Predicted)
• 密度：
  1.344±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  4-甲基-6-硝基喹啉-2-醇 在 palladium 10% on activated carbon 、 氢气 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 54.0h， 生成 4-methyl-2-(4-methylpiperazin-1-yl)quinolin-6-ylamine
  参考文献：
  名称：

  Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors

  摘要：

  In order to discover novel Hsp90 inhibitors targeting the C-terminal ATP binding pocket, a novobiocin derivative based ROCS model was constructed for virtual screening. Compound 13 was identified as the lead compound and then systematical structure activity relationship (SAR) study was conducted. These efforts led to compound 69, which exhibited potent anti-proliferative activities against MCF7 and SKBr3 breast cancer cell lines. In 4T1 mice breast cancer models, 69 exhibited potent tumor growth inhibition and anti-metastasis effect. Compound 69 as a potent antitumor agent targeting the Hsp90 C-terminal is worthy of further pre-clinical study. (C) 2017 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2017.07.080
• 作为产物：
  描述：

  乙酰乙酰对硝基苯胺 在 硫酸 作用下， 生成 4-甲基-6-硝基喹啉-2-醇
  参考文献：
  名称：

  CCCIII.—4-甲基-，4：6-，4：7-和4：8-二甲基-2-羟基喹啉的衍生物

  摘要：

  DOI：

  10.1039/jr9300002346

文献信息

• RETRACTED ARTICLE: An environmentally benign one pot synthesis of substituted quinolines catalysed by fluoroboric acid based ionic liquid
  作者：A RAJENDRAN、C KARTHIKEYAN、K RAJATHI、D RAGUPATHY

  DOI：10.1007/s12039-012-0272-y

  日期：2012.7

  using an ionic liquid [Et3NH] + [BF4]\(^-}_\thinspace }\)as catalyst. All the reactions gave products with high degree of purity and excellent yield (78–93%) within the shorter span of time (20–65 min) than those reactions with conventional methods. The screening of solvents as well as the reuse of ionic liquid has been evaluated. The structure of the products has been elucidated by spectral and analytical

  有机合成通常需要大量的溶剂，避免在合成中使用有机溶剂是一种旨在发展良性化学的范式转变，而离子液体令人惊讶地可以导致获得新化合物。通过使用离子液体[Et 3 NH]  +  [BF 4 ] \（^ -} _ \}在乙醇中于60°C在乙醇中将取代的苯胺与β-酮酸酯反应，可以实现一种精致的一锅合成喹啉衍生物。稀薄空间} \）作为催化剂。与传统方法相比，所有反应在较短的时间段（20-65分钟）内都能提供高纯度的产品和优异的收率（78-93％）。已经评估了溶剂的筛选以及离子液体的再利用。通过光谱和分析数据阐明了产品的结构。反应的当前范围和潜在的经济影响通过取代喹啉的合成证明。讨论了新转型的剩余挑战和未来前景。 在60°C的乙醇中，使用离子液体[Et 3 NH] + [BF 4 ] –作为催化剂，可以轻松完成一锅喹啉衍生物的合成。与常规方法相比，所有反应均能提供具有高纯度和优异产率（78-93％）的产物。
• [EN] SUBSTITUTED QUINOLINES AS MCR MODULATORS<br/>[FR] QUINOLEINES SUBSTITUEES, UTILISEES COMME MODULATEURS DE LA MCH
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2005035521A1

  公开（公告）日：2005-04-21

  Quinolines of formula (I) are useful as MCH mediators, and in the therapy of obesity.

  式(I)的喹啉在MCH介质和肥胖治疗中很有用。
• Photolytic ring-expansions of 6-azidoquinolines and 6-azidodiazines: some unexpected azepine ring-opening reactions
  作者：Roy Hayes、Joseph M. Schofield、Robert K. Smalley、David I.C. Scopes

  DOI：10.1016/s0040-4020(01)89775-1

  日期：1990.1

  Photolysis of 6-azidoquianazoline in MeOH-KOMe-dioxan yields 8,9-dihydro-5,7-dimethoxy-5H-pyrimido[5,4-]azepine (5) which on acid hydrolysis ring-opens to the pyrimidine-carbaldehyde (7). The mechanism of formation of this unexpected dimethoxypyrimido-azepine is discussed and related to previous similar results involving 6-azido-2,3-dihydrofuro- and 6-azido-23-dihydrothieno-[2,3-b]quinolines

  6-叠氮喹啉在MeOH-KOMe-二恶烷中的光解产生8,9-二氢-5,7-二甲氧基-5H-嘧啶并[5,4-]氮杂（5），在酸水解时开环反应成嘧啶-甲醛（ 7）。讨论了这种意外的二甲氧基嘧啶基-氮杂a的形成机理，并与先前涉及6-叠氮基-2,3-二氢呋喃基和6-叠氮基-23-二氢噻吩基-[2,3-b]喹啉的类似结果相关联
• Quinoline compounds for use in mch receptor related disorders
  申请人：Frimurer Michael Thomas

  公开号：US20060111357A1

  公开（公告）日：2006-05-25

  The present invention relates to the use of quinoline compounds for the preparation of a pharmaceutical and/or a cosmetic composition for the treatment, prophylaxis and/or diagnosis of a condition caused by or involving a melanin-concentrating hormone. The invention also relates to novel quinoline compounds per se. The quinoline compounds have been found to interact with a melanin-concentrating hormone receptor, a MCH receptor. The compounds have modulating activity on the MCH receptor such as e.g. antagonistic, agonistic or allosteric activity and are useful for medicinal or cosmetic purposes such as, e.g. in the treatment or prevention of feeding disorders like obesity, metabolic syndrome, Type II diabetes, bulimia, etc. or in the treatment or prevention of depression.

  本发明涉及使用喹啉化合物制备用于治疗、预防和/或诊断由或涉及黑色素浓缩激素引起的疾病的药物和/或化妆品组合物。本发明还涉及新型喹啉化合物本身。已发现喹啉化合物与黑色素浓缩激素受体（MCH受体）相互作用。该化合物对MCH受体具有调节活性，例如拮抗、激动或异构活性，并可用于药用或化妆品用途，例如治疗或预防饮食障碍，如肥胖症、代谢综合征、2型糖尿病、贪食症等，或治疗或预防抑郁症。
• Kidwai, Mazaahir; Bansal, Vikas; Mishra, Neeraj Kumar, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2009, vol. 48, # 5, p. 746 - 748
  作者：Kidwai, Mazaahir、Bansal, Vikas、Mishra, Neeraj Kumar、Bhatnagar, Divya

  DOI：——

  日期：——

表征谱图